top of page

Dr Paul Brennan joins the Dxcover Scientific Advisory Board

Dxcover® are delighted to announce the appointment of Dr Paul Brennan to their Scientific Advisory Board (SAB).


Dr Brennan is a Reader and Consultant Neurosurgeon at the University of Edinburgh and NHS Lothian. He has a strong track record leading clinical trials and laboratory research, with major focus on brain tumours. Furthermore, he has significant experience as med-tech medical advisor, as well as a founder of University spin-out eoSurgical Ltd, providing surgical simulation training around the world.


Dr Paul Brennan, Neurosurgeon and SAB member, said: “The challenge with diagnosing brain tumours is identifying those patients who are most likely to have a tumour and prioritising them for an urgent scan. Dxcover® have developed a liquid biopsy test which has the potential to speed up diagnosis and get patients treated as quickly as possible.


"I am delighted to continue working with the team and aid them in achieving their mission to become a world leader in liquid biopsy for the early detection of cancers and other diseases”.


Chief Technical Officer, Dr Matthew J Baker, said: "It is excellent to be able to attract a leading clinician of Paul's standing to our advisory board. Our collaboration over the years has proven the utility of the Dxcover® Brain Cancer Liquid Biopsy in two prospective clinical studies and I look forward to working with Paul to bring this test into the clinic for patient use"


For further information about the scientific advisory board, please contact info@dxcover.com.

Recent Posts

See All

May is Brain Cancer Awareness Month

Timely Focus on Brain Cancer Early Detection May 29, 2024 GLASGOW, Scotland--Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis (MOSA) for early detectio

Comments


bottom of page